Long-Term Safety Study of Vildagliptin in Patients With Type 2 Diabetes

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study is not being conducted in the United States. Vildagliptin is an oral antidiabetic agent. This 52-week clinical study is designed as an open label, long-term study aimed to evaluate the safety of vildagliptin in patients with type 2 diabetes.

• Phase: Phase 3

Details

• Lead Sponsor: Novartis
• Treatments: Vildagliptin

Criteria

Inclusion Criteria:

• Diagnosis of type 2 diabetes

• Patients who have been placed on diet and exercise therapy without achieving target blood glucose levels

• Outpatients

Exclusion Criteria:

• Type 1 diabetes, diabetes that is a result of pancreatic injury, or secondary forms of diabetes

• Significant cardiovascular complications as defined by the protocol

• Significant diabetic complications as defined by the protocol

Other protocol-defined inclusion/exclusion criteria may apply